Soc. Generale Call 720 LLY 19.06..../ DE000SU550Z6 /
2024-06-03 5:54:09 PM | Chg.+0.090 | Bid2024-06-03 | Ask2024-06-03 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
2.240EUR | +4.19% | 2.250 Bid Size: 175,000 |
2.260 Ask Size: 175,000 |
ELI LILLY | 720.00 - | 2026-06-19 | Call |
GlobeNewswire
6:00 AM
BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Disease...
GlobeNewswire
2:00 AM
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
GlobeNewswire
05-30
Sermonix Pharmaceuticals to Present Poster on ELAINE-3 Trial in Progress at ASCO 2024
GlobeNewswire
05-30
Anaqua Annual User Experience Conference to Feature Keynotes from Microsoft, SAP, USPTO, and More
GlobeNewswire
05-24
Gov. Holcomb Joins Lilly to Announce Additional $5.3 Billion Investment at LEAP District
GlobeNewswire
05-23
Amphista Therapeutics unveils new differentiated mechanism of action for BRD9 degradation at 2024 Pr...
GlobeNewswire
05-16
BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED ...
GlobeNewswire
05-16
Totus Medicines Announces Strategic Multi-Target Research Collaboration with Lilly
GlobeNewswire
05-15
Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member
GlobeNewswire
05-13
Lycia Therapeutics Completes $106.6 Million Series C Financing to Advance Pipeline of LYTAC Extracel...
GlobeNewswire
05-09
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire
05-09
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radioph...
GlobeNewswire
05-08
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
GlobeNewswire
05-08
Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegener...
GlobeNewswire
05-08
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting...
GlobeNewswire
05-08
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results